16 September 2026 editorial review · Trial
TUFF-IPC Phase 1/2a: autologous adipose-derived insulin-producing cells: review notes
These notes document the scope actually reviewed, including source-access limits. They are not independent clinical certification or a guarantee that every claim was verified.
Read the trial evidence page →Primary-agent trial review — 16 September 2026
Assessment: Current jRCT entry retrieved via indexed primary record: recruiting, last updated May 18; first enrollment January 27, 2026; three planned participants aged 18–65. Updated registry dates; no efficacy results.
Sources for this record: jRCT2063250055: TUFF-IPC autologous adipose-derived IPCs in T1D (registry).
Limits: Source access and review depth vary. Registry fields establish the registered study, not clinical benefit, product approval or current local access. Cited-source reachability alone was not treated as verification of its claims.